Disease · MONDO_0015545
macrophage activation syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. macrophage activation syndrome. Diseases, record MONDO_0015545. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015545
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| EMAPALUMAB | CHEMBL3989977 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RUXOLITINIB | CHEMBL1789941 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| INTERFERON GAMMA-1B | CHEMBL1201564 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TOCILIZUMAB | CHEMBL1237022 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALDESLEUKIN | CHEMBL1201438 | Protein | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets13
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IFNG | Interferon gamma | 1 | Interferon gamma inhibitor | Phase 3 | https://conductscience.org/library/genes/3458 | Drugs and targets |
| IFNGR1 | Interferon gamma receptor | 1 | Interferon gamma receptor agonist | Phase 2 | https://conductscience.org/library/genes/3459 | Drugs and targets |
| IFNGR2 | Interferon gamma receptor | 1 | Interferon gamma receptor agonist | Phase 2 | https://conductscience.org/library/genes/3460 | Drugs and targets |
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| IL2RA | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/3559 | Drugs and targets |
| IL2RB | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/3560 | Drugs and targets |
| IL2RG | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/3561 | Drugs and targets |
| IL6R | Interleukin-6 receptor subunit alpha | 1 | Interleukin-6 receptor alpha subunit inhibitor | Phase 2 | https://conductscience.org/library/genes/3570 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 1 | Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 1 | Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
1 to 10 of 13
See all 13 targetsTrials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02069899 | A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody | Phase 2/3 | 58 | 2022-06-28 | Hemophagocytic Lymphohistiocytosis | EMAPALUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT05001737 | Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE | Phase 3 | 33 | 2026-02-19 | Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS | EMAPALUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03311854 | A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) | Phase 2 | 14 | 2022-01-26 | Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease | EMAPALUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04339712 | Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction | Phase 2 | 102 | COVID-19, Virus Diseases, Macrophage Activation Syndrome, Corona Virus Infection | ANAKINRA, TOCILIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05137496 | Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome | Phase 3 | 40 | Macrophage Activation Syndrome | METHYLPREDNISOLONE, RUXOLITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03332225 | A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis | Phase 2 | 36 | Sepsis, Macrophage Activation Syndrome | ANAKINRA, INTERFERON GAMMA-1B | Its record names the disease | ClinicalTrials.gov | |
| NCT02780583 | Treatment of Macrophage Activation Syndrome (MAS) With Anakinra | Phase 1 | 9 | Macrophage Activation Syndrome | ANAKINRA | Its record names the disease | ClinicalTrials.gov | |
| NCT02569463 | Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS） | Phase 1/2 | 6 | Macrophage Activation Syndrome | ALDESLEUKIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Laboratory Parameters | 0 of 25 | 0 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Study Interruption Due to Safety Reasons | 1 of 25 | 1 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Withdrawal From the Study Due to Lack of Response | 0 of 25 | 0 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Adverse Events (AEs) (Serious and Non-serious). | 24 of 25 | 8 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Survival | 23 of 25 | 8 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Proportion of Subjects With Overall Response as Defined by CR or Partial Response (PR) | 16 of 25 | 6 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab | 11 of 25 | 4 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): deaths from any cause | 2 of 25 | 0 of 8 | 33 | NCT05001737 | Trial comparisons |
Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): Number of Patients With Glucocorticoids (GC)s Tapering to a Dose Below 50% of Prednisolone (PDN) Equivalent at the Time of Emapalumab Start or to the Same (or Lower) Dose Being Administered Before the Occurrence of MAS Whichever Occurs First | 15 of 25 | 7 of 8 | 33 | NCT05001737 | Trial comparisons |
| Cohort 1 (sJIA and AOSD) vs Cohort 2 (SLE): serious adverse events | 18 of 25 | 4 of 8 | 33 | NCT05001737 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials20
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015545
GET https://conductscience.org/api/diseases/v1/MONDO_0015545/drugs